Methylprednisolone disposition kinetics in patients with acute spinal cord injury. 1998

J L Segal, and B F Maltby, and M I Langdorf, and R Jacobson, and S R Brunnemann, and W J Jusko
Medical and Spinal Cord Injury Service, Department of Veterans Affairs Medical Center, Long Beach, California 90822, USA.

OBJECTIVE To evaluate the pharmacokinetics of high-dose methylprednisolone in patients with acute spinal cord injury (ASCI). METHODS Open-label study of consecutive patients with ASCI, and retrospective review of able-bodied controls. METHODS Emergency Medicine Department of a large, urban, university-affiliated, tertiary care trauma center. METHODS Eleven men with ASCI. METHODS Methylprednisolone sodium succinate 30 mg/kg intravenous bolus, followed by 5.4 mg/kg/hour for 23 hours, administered according to the second National Acute Spinal Cord Injury Study (NASCIS 2) protocol. RESULTS The total systemic clearance of methylprednisolone was significantly less in acutely injured patients (mean +/- SD 30.04 +/- 12.03 L/hr) than in historically reported able-bodied controls (44.70 +/- 4.90 L/hr). An inverse correlation between the neurologic level of injury and systemic clearance was seen. No differences in volume of distribution were discernible between patients (126.90 L) and controls (135.45 L). CONCLUSIONS Patients with acute spinal cord injury administered methylprednisolone according to the NASCIS 2 protocol had an apparent decrease in total systemic clearance of the drug without a commensurate change in volume of distribution. Additional studies are warranted to confirm these findings and assess the potential impact of diminished clearance on the efficacy of the agent in ASCI.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

J L Segal, and B F Maltby, and M I Langdorf, and R Jacobson, and S R Brunnemann, and W J Jusko
February 1985, Paraplegia,
J L Segal, and B F Maltby, and M I Langdorf, and R Jacobson, and S R Brunnemann, and W J Jusko
August 1992, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses,
J L Segal, and B F Maltby, and M I Langdorf, and R Jacobson, and S R Brunnemann, and W J Jusko
September 1990, American journal of hospital pharmacy,
J L Segal, and B F Maltby, and M I Langdorf, and R Jacobson, and S R Brunnemann, and W J Jusko
March 2001, The New Zealand medical journal,
J L Segal, and B F Maltby, and M I Langdorf, and R Jacobson, and S R Brunnemann, and W J Jusko
January 1984, JAMA,
J L Segal, and B F Maltby, and M I Langdorf, and R Jacobson, and S R Brunnemann, and W J Jusko
August 1994, Critical care nurse,
J L Segal, and B F Maltby, and M I Langdorf, and R Jacobson, and S R Brunnemann, and W J Jusko
June 2013, Postepy higieny i medycyny doswiadczalnej (Online),
J L Segal, and B F Maltby, and M I Langdorf, and R Jacobson, and S R Brunnemann, and W J Jusko
April 1983, The Journal of the American Paraplegia Society,
J L Segal, and B F Maltby, and M I Langdorf, and R Jacobson, and S R Brunnemann, and W J Jusko
January 2021, Frontiers in pharmacology,
J L Segal, and B F Maltby, and M I Langdorf, and R Jacobson, and S R Brunnemann, and W J Jusko
April 2008, Journal of neurosurgical anesthesiology,
Copied contents to your clipboard!